Posts by John

New research shows lower plasminogen levels trigger faster liver repair. Discover the implications for post-surgical recovery and regenerative medicine.

A major medical journal retracts a study on cancer therapy timing due to data errors. Learn why rigorous evidence remains vital for oncology protocols.

The FDA has approved a breakthrough pediatric diabetes treatment. Discover how this new therapy is set to improve glycemic control and patient outcomes.

A new oral heart failure drug reports high safety and tolerability in a 58-patient clinical trial. Learn about this breakthrough in cardiac care.

Imagion Biosystems raises AU$3.75M to fund a Phase 2 clinical trial after receiving FDA clearance for its innovative cancer diagnostic technology.

Europe launches a €15M project to develop bacteriophage therapies as a powerful, targeted alternative to antibiotics in the fight against superbugs.

Servier has enrolled the first patient in a U.S. Phase Ib/II trial for a rare pediatric epilepsy syndrome, marking a key step in developing new treatments.

Viking Therapeutics has launched a Phase 1 trial for VK3019. Explore the safety, objectives, and clinical implications of this new drug development initiative.

New South African research is revolutionizing global tuberculosis treatment, introducing shorter, safer regimens to replace outdated clinical standards.

The FDA has rejected the NDA for cytisinicline due to manufacturing issues. Clinical safety and efficacy data remain strong; approval awaits process updates.